Glyco-engineering of moss lacking plant-specific sugar residues.
about
Use of endogenous signal sequences for transient production and efficient secretion by moss (Physcomitrella patens) cells.Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needsAlgal Cell Factories: Approaches, Applications, and PotentialsProduction of biologically active recombinant human factor H in PhyscomitrellaMoss and liverwort xyloglucans contain galacturonic acid and are structurally distinct from the xyloglucans synthesized by hornworts and vascular plants.Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.Protein N-glycosylation in eukaryotic microalgae and its impact on the production of nuclear expressed biopharmaceuticals.DICER-LIKE3 activity in Physcomitrella patens DICER-LIKE4 mutants causes severe developmental dysfunction and sterility.Moss systems biology en route: phytohormones in Physcomitrella development.On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect.A human anti-Pseudomonas aeruginosa serotype O6ad immunoglobulin G1 expressed in transgenic tobacco is capable of recruiting immune system effector function in vitro.Moss-made pharmaceuticals: from bench to bedside.Identification of Targets and Interaction Partners of Arginyl-tRNA Protein Transferase in the Moss Physcomitrella patens.Production of therapeutic antibodies with controlled fucosylation.Inactivation of the β(1,2)-xylosyltransferase and the α(1,3)-fucosyltransferase genes in Nicotiana tabacum BY-2 Cells by a Multiplex CRISPR/Cas9 Strategy Results in Glycoproteins without Plant-Specific Glycans.Plant glycans: friend or foe in vaccine development?Plant-derived vaccines and other therapeutics produced in contained systems.Glycoprotein production in moss bioreactors.Plant biofarming: novel insights for peptide expression in heterologous systems.The potential of Physcomitrella patens as a platform for the production of plant-based vaccines.Glyco-engineering for biopharmaceutical production in moss bioreactors.Characterization of the single-chain Fv-Fc antibody MBP10 produced in Arabidopsis alg3 mutant seeds.Implications of plant glycans in the development of innovative vaccines.Perspectives on using physcomitrella patens as an alternative production platform for thapsigargin and other terpenoid drug candidates.An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice.Targeted gene knockouts reveal overlapping functions of the five Physcomitrella patens FtsZ isoforms in chloroplast division, chloroplast shaping, cell patterning, plant development, and gravity sensingA gene responsible for prolyl-hydroxylation of moss-produced recombinant human erythropoietin.Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants.Expression of natural human β1,4-GalT1 variants and of non-mammalian homologues in plants leads to differences in galactosylation of N-glycans.High-level expression of secreted complex glycosylated recombinant human erythropoietin in the Physcomitrella Delta-fuc-t Delta-xyl-t mutant.
P2860
Q24811666-A17E12D5-1129-40E7-9DFC-71DCDEB112A7Q26795434-9988E42A-18D3-49AB-AB10-AB8B1370FF7AQ28067621-0690D234-A23D-477E-AFD6-9B3EE2AAEB5BQ28290970-CCF16FC1-CADB-455C-8F0C-13AFB6190DC1Q33360217-62A701BC-3EF4-47F6-9BF3-616E5D772C1FQ33437488-41569910-1976-411F-97E6-43DD974956A3Q34054932-2D41823D-24C2-4F24-898F-C9D682606B02Q34236448-3824055C-383D-4AE2-9D06-C0280C6AAFCBQ34542861-D40ABD70-F1FD-4BA7-935D-30301321C0FFQ35002326-937D75CC-38EF-4F87-BFC2-D547F0479A4AQ36094806-28C88832-DCE5-45A6-BB5A-10E26FA2FBEDQ36530505-8491FB84-E3BB-4DE9-B389-41B05B189651Q37372346-ED9A3304-8CA0-46F3-9696-9C2702805FF0Q37672128-C320B748-B9B9-45F5-BA36-DB1493118C3BQ37721260-6B119104-65D5-4952-A073-CF22FD50F3DAQ37776714-E1FF5A34-B878-44C6-998B-7FEBE043EB98Q37776718-F5A3E234-4D48-4316-B2F0-9AA43FBB8177Q37940883-196B3287-A604-429A-81FB-71DA2A3E9489Q38063510-D9C67EBA-07DF-4469-BC91-77A6A05FF686Q38176986-40C4DBC4-9F02-44FE-AABD-CD1D32C7FF7CQ38234961-6117E0CF-E553-4754-9077-CE017C768029Q38463584-CE46CC67-7BFC-45AD-B2A2-13E6393A4D55Q38738762-1FADCCC7-AD3B-4D42-88A1-849A6DBFCF42Q39940667-E0496DF6-7473-4C3F-A908-AA84FE1B48ABQ41725365-4964DC14-75EF-4F85-89AD-25B62414CB20Q41981812-CC3C44EA-F96F-47E6-BFC3-CE7CB1FCAB2FQ42044055-08531032-09EB-4E20-9E38-A0A86D408B7BQ45716164-598CAF65-0789-4452-BC46-3E44065EB186Q46857785-7993A7A4-034C-4B75-B8D8-817DA1F360AEQ51048011-2DB31DC7-30A7-417D-A30C-6023BB1E68F6
P2860
Glyco-engineering of moss lacking plant-specific sugar residues.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Glyco-engineering of moss lacking plant-specific sugar residues.
@en
Glyco-engineering of moss lacking plant-specific sugar residues.
@nl
type
label
Glyco-engineering of moss lacking plant-specific sugar residues.
@en
Glyco-engineering of moss lacking plant-specific sugar residues.
@nl
prefLabel
Glyco-engineering of moss lacking plant-specific sugar residues.
@en
Glyco-engineering of moss lacking plant-specific sugar residues.
@nl
P2093
P2860
P356
P1433
P1476
Glyco-engineering of moss lacking plant-specific sugar residues.
@en
P2093
Huether CM
Lienhart O
P2860
P304
P356
10.1055/S-2005-837653
P577
2005-05-01T00:00:00Z